Business that Never Ends

0 +
Medical Platform in different specialties
0 +
Users
0 +
Impressions

Our Focus

Our teams, equipped with our range of specialised services, provide accurate and relevant information that will help you make smarter decisions, faster and more consistently across markets

Healthcare Firms
Learn More
Medical technologies
Learn More
Environment
Learn More

Our Products

We develop innovative, patented, and exclusive digital platforms in the form of mobile applications and websites with a focus on the healthcare industry

latest News
11 December 2024
Newly reported from ESC 2024 - Aficamten in the Spotlight at ESC Congress, with Ahmad Masri, MD, MS - [Cloned #5940]
Newly reported from ESC 2024 – Aficamten in the Spotlight at ESC Congress, with Ahmad Masri, MD,...
Read More
26 September 2024
Newly reported from EULAR 2024: Long COVID Linked to Significantly Worse Rheumatic Disease Activity
Newly reported from EULAR 2024: Long COVID Linked to Significantly Worse Rheumatic Disease Activity COVID-19...
Read More
26 September 2024
News Coverage from EULAR 2024: Arthritis Disease Severity Peaks in Spring and Fall, According to PROs
News Coverage from EULAR 2024: Arthritis Disease Severity Peaks in Spring and Fall, According to PROs...
Read More
26 September 2024
Broadcasting from EULAR 2024: Anxiety Plays a Significant Role in Physical Activity Avoidance Among Patients with PsA
Broadcasting from EULAR 2024: Anxiety Plays a Significant Role in Physical Activity Avoidance Among Patients...
Read More
26 September 2024
Newly reported from EULAR 2024: Ketogenic Diet Intervention Improves Psoriatic Arthritis Symptoms
Newly reported from EULAR 2024: Ketogenic Diet Intervention Improves Psoriatic Arthritis Symptoms A very...
Read More
26 September 2024
Reporting from EULAR 2024: Gout Remission Achieved in Approximately Half of Patients Treated with Pegloticase
Reporting from EULAR 2024: Gout Remission Achieved in Approximately Half of Patients Treated with Pegloticase...
Read More
26 September 2024
Newscasting from EULAR 2024: Approximately Half of Patients Demonstrated Poor Health Literacy Prior to Biosimilar Switch
Newscasting from EULAR 2024: Approximately Half of Patients Demonstrated Poor Health Literacy Prior to...
Read More
26 September 2024
News Coverage from EULAR 2024: Denosumab Biosimilar SB16 Demonstrates Bioequivalence up to 18 Months
News Coverage from EULAR 2024: Denosumab Biosimilar SB16 Demonstrates Bioequivalence up to 18 Months...
Read More
26 September 2024
Directly from EULAR 2024 - Jacques-Eric Gottenberg, MD, PhD: Promising Phase 2 Results for Nipocalimab in Sjögren's Treatment
Directly from EULAR 2024 – Jacques-Eric Gottenberg, MD, PhD: Promising Phase 2 Results for Nipocalimab...
Read More
26 September 2024
Broadcasting from EULAR 2024: Dotinurad Demonstrates Superiority to Febuxostat for the Treatment of Gout
Broadcasting from EULAR 2024: Dotinurad Demonstrates Superiority to Febuxostat for the Treatment of Gout...
Read More